ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "quality of life"

  • Abstract Number: 557 • 2019 ACR/ARP Annual Meeting

    Comparing Symptoms, Treatments Patterns, and Quality of Life of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients: Findings from a US Survey

    Theresa Hunter1, David Sandoval 2, Nicola Booth 3, Elizabeth Holdsworth 4 and Atul Deodhar 5, 1Eli Lilly and Company, Indianapolis, 2Eli Lilly and Company, Indianapolis, IN, 3Adelphi Real World, Bollington, United Kingdom, 4Adelphi Real World, Manchester, England, United Kingdom, 5Oregon Health & Science University, Portland, OR

    Background/Purpose: To better understand the symptoms, clinical characteristics, treatment patterns, and quality of life (QoL), of non-radiographic axial spondyloarthritis (nr-axSpA) patients and how they compare…
  • Abstract Number: 1120 • 2019 ACR/ARP Annual Meeting

    Prevalence of Burnout in Rheumatology Professionals

    Vivekanand Tiwari1, Arthur Kavanaugh 2, George Martin 3 and Martin Bergman 4, 1Temple University, Philadelphia, PA, 2University of California, San Diego School of Medicine, La Jolla, CA, 3Dr. George Martin Dermatology Associates, Kihei, HI, 4Drexel University College of Medicine, Stockholm, Sweden

    Background/Purpose: Burnout among physicians has major implications for health care. We measured prevalence of burnout in a large group of Rheumatology professionals attending a national…
  • Abstract Number: 1258 • 2019 ACR/ARP Annual Meeting

    Effects of Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody, on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 1-Year Results of a Phase III Trial

    John Reveille1, Atul Deodhar 2, Diane Harrison 3, Elizabeth Hsia 4, Eric K H Chan 3, Shelly Kafka 5, Kim Hung Lo 3, Lilianne Kim 3 and Chenglong Han 3, 1University of Texas McGovern Medical School, Houston, 2Oregon Health & Science University, Portland, OR, 3Janssen Research & Development, LLC, Spring House, PA, 4Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, 5Janssen Scientific Affairs, LLC, Horsham, PA

    Background/Purpose: In patients with ankylosing spondylitis (AS), IV administration of the anti-TNFa antibody golimumab (GLM-IV) resulted in improvements in composite measures of various aspects of…
  • Abstract Number: 1466 • 2019 ACR/ARP Annual Meeting

    Evaluation of Changes in Oral Health-Related Quality of Life over Time in Patients with Sjögren’s Syndrome

    Naoto Azuma1, Yoshinori Katada 2, Aki Nishioka 3, Masahiro Sekiguchi 4, Masayasu Kitano 5, Sachie Kitano 1, Hajime Sano 6 and Kiyoshi Matsui 1, 1Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, 2Department of Rheumatology, Sakai City Medical Center, Sakai, Japan, 3Department of Rheumatology, Nishinomiya Watanabe Hospital, Nishinomiya, Japan, 4Departement of Rheumatology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan, 5Department of Rheumatology, Kyoto Okamoto Memorial Hospital, Kumiyama, Japan, 6Kyoto Okamoto Memorial Hospital, Kumiyama, Japan

    Background/Purpose: In addition to xerostomia symptoms, patients with Sjögren’s syndrome (SS) experience pain and discomfort in the oral cavity, and difficulties in speaking and eating,…
  • Abstract Number: 1539 • 2019 ACR/ARP Annual Meeting

    Ustekinumab and TNF Inhibitors Similarly Improve Patient-perceived Impact of Psoriatic Arthritis but Differentially Affect the Scale Subdomains: Results from a European Observational Cohort Study

    Laure Gossec1, Stefan Siebert 2, Paul Bergmans 3, Kurt De Vlam 4, Elisa Gremese 5, Beatriz Joven-Ibáñez 6, Ellie Korendowych 7, Tatiana Korotaeva 8, Wim Noël 9, Michael Nurmohamed 10, Christophe Richez 11, Petros Sfikakis 12, Pavel Smirnov 13, Elke Theander 14 and Josef Smolen 15, 1Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 2Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, 3Biostatistics and Medical Affairs, Janssen, Tilburg, Netherlands, 4University Hospitals Leuven, Leuven, Belgium, 5Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy, 6Hospital Universitario 12 de Octubre, Madrid, Spain, 7Royal National Hospital for Rheumatic Diseases, Bath, Bath, United Kingdom, 8Nasonova Research Institute of Rheumatology, Moscow, Russia, 9Biostatistics and Medical Affairs, Janssen, Brussels, Belgium, 10Reade and VU Rheumatology Research Department, Amsterdam, Netherlands, 11Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, 12Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, 13Biostatistics and Medical Affairs, Janssen, Moscow, Russia, 14Biostatistics and Medical Affairs, Janssen, Solna, Sweden, 15Medical University of Vienna, Vienna, Austria

    Background/Purpose: Psoriatic arthritis strongly impacts patients’ quality of life (QoL). Insights on the effects of biologic treatments on different domains of health-related QoL in a…
  • Abstract Number: 624 • 2018 ACR/ARHP Annual Meeting

    Easy Accessibility of Biologics and Its Impact on Disease Activity and Quality of Life in Kuwaiti Patients with Rheumatoid Arthritis

    Adeeba Al-Herz1, Khulood Saleh2, Adel Al-Awadhi3, Waleed Al-Kandari2, Eman Hasan4, Aqeel Ghanem5, Yaser Ali5, Hebah Alhajeri6, Sawsan Hayat5, Ali Aldei7, Mohammad Hussain4, Ibrahim Nahar5, Fatemah Abutiban8, Ahmad Alenizi8, Khaled Mokaddem1, Ahmad Khadrawy2, Ammad Fazal2, Agaz Zaman5, Ghada Mazloum5, Youssef Bartella1, Sally Hamed1, Ramia Alsouk8 and Ahmed Al-Saber9, 1Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, 2Rheumatology, Farwania Hospital, Farwania, Kuwait, 3Faculty of Medicine, Kuwait, Kuwait, 4Al-Amiri Hospital, Kuwait city, Kuwait, 5Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, 6Division of Rheumatology, Mubarak Al-Kabeer Hospital, hawalli, Kuwait, 7Rheumatology, Al-Amiri Hospital, Kuwait City, Kuwait, 8Rheumatology, Jahra Hospital, Jahra, Kuwait, 9Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait

    Background/Purpose: Prescribing biologics for patients with rheumatoid arthritis (RA) may be restricted by many factors other than the physician’s clinical judgment. In Kuwait, patients with…
  • Abstract Number: 1385 • 2018 ACR/ARHP Annual Meeting

    Subjective Well-Being Among Rheumatoid Arthritis Patients

    Goichi Kageyama1,2, Akira Onishi3, Yo Ueda3, Kengo Akashi3, Sho Sendo3, Jun Saegusa3 and Akio Morinobu2, 1Department of Rheumatology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan, 2Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 3Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan

    Background/Purpose: Subjective well-being (SWB) is a psychological construct that is synonymous with happiness. Many variables including age, sex, income, employment, and marital status are related…
  • Abstract Number: 1923 • 2018 ACR/ARHP Annual Meeting

    Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?

    Elena Nikiphorou1, Sam Norton2, Adam Young3, Lewis Carpenter2, Josh Dixey4, David Walsh5 and Patrick Kiely6, 1Academic Rheumatology, Department of Inflammation Biology, King's College London, London, Great Britain, 2Academic Rheumatology, King's College London, London, United Kingdom, 3University of Hertfordshire, Hertford, United Kingdom, 4Rheumatology, The Royal Wolverhampton, Wolverhampton, United Kingdom, 5Academic Rheumatology, University of Nottingham, Nottingham, Great Britain, 6Rheumatology Dept, St Georges Hospital, London, Great Britain

    Treating Rheumatoid Arthritis To Target: Is Low Disease Activity Good Enough? Background/Purpose:  It is now widely recognised that treat-to-target (T2T) principles in rheumatoid arthritis (RA)…
  • Abstract Number: 1767 • 2017 ACR/ARHP Annual Meeting

    The Effect on Health-Related Quality of Life of Treatment for Remission Maintenance in ANCA-Associated Vasculitis Beyond 18 Months

    Gunnar Tomasson1, Antoine G. Sreih2, David Cuthbertson3, Simon Carette4, Nader A. Khalidi5, Curry L. Koening6, Carol A. Langford7, Carol A. McAlear8, Paul A. Monach9, Larry W. Moreland10, Philip Seo11, Ulrich Specks12, Steven R. Ytterberg13 and Peter A. Merkel14, 1University of Iceland, Faculty of Medicine, Reykjavik, IS, 2Rheumatology, University of Pennsylvania, Philadelphia, PA, 3Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, 4Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5Rheumatology, McMaster University, Hamilton, ON, Canada, 6Rheumatology, University of Utah, Salt Lake City, UT, 7Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 8University of Pennsylvania, Philadelphia, PA, 9Boston University School of Medicine, Boston, MA, 10Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 11Medicine, Johns Hopkins University, Baltimore, MD, 12Mayo Clinic College of Medicine, Rochester, MN, 13Rheumatology, Mayo Clinic, Rochester, MN, 14Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Standard management of ANCA-associated vasculitis (AAV) involves treatment with immunosuppressive agents for at least 18 months.  Treatment beyond 18 months reduces the rates of…
  • Abstract Number: 2258 • 2017 ACR/ARHP Annual Meeting

    Real-World Evidence Linking Health-Related Quality of Life to Work Outcomes in Patients with Rheumatoid Arthritis

    Vibeke Strand1, Mark Kosinski2, Regina Rendas-Baum2, David Brooks3 and Rita Ganguly4, 1Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 2Optum, Inc, Eden Prairie, MN, 3GlaxoSmithKline, Philadelphia, PA, 4GlaxoSmithKline, Collegeville, PA

    Background/Purpose: Evaluating health-related quality of life (HRQoL) scores is a key component of the management of rheumatoid arthritis (RA) and evaluation of treatment efficacy.  There…
  • Abstract Number: 2769 • 2017 ACR/ARHP Annual Meeting

    Predictive Value of Leisure-Time Physical Activity in Women with Systemic Erythematosus Lupus on Physical and Mental Health

    Alix St-Aubin1, Anne-Sophie Julien2, Carolyn Neville3, Ellie Aghdassi4, Stacey Morrison5, Jiandong Su6, Janet E. Pope7, Sara Hewitt8, Christian Pineau9, Paula Harvey10, Michal Abrahamowicz11, Deborah Da Costa12, Paul Poirier13 and Paul R. Fortin14, 1Division of Rheumatology, Department of Medicine, CHU de Québec – Université Laval, Quebec, QC, Canada, 2CHU de Quebec - Universite Laval, Quebec City, QC, Canada, 3Department of Medicine, McGill University Health Center, Montreal, QC, Canada, 4Epidemiology Division, The Toronto Western Hospital, Toronto, ON, Canada, 5Rheumatology, Krembil Research Institute, Toronto, ON, Canada, 6Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 7Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 8Department of Medicine, Division of Rheumatology, University of Western Ontario, St-Joseph Health Care, London, ON, Canada, 9Rheumatology, McGill University Health Center, Montreal, QC, Canada, 10Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, 11Department of Medicine, McGill University Health Centre, Montreak, QC, Canada, 12Department of Medicine, McGill University Health Center, Montréal, Quebec, Canada., Montreal, QC, Canada, 13Deparment of Medicine, Division of Cardiology, Institut universitaire de cardiologie et de pneumologie de Québec and Université Laval, Quebec City, QC, Canada, 14Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is associated with a higher mortality due to higher risk of cardiovascular events. Although…
  • Abstract Number: 2955 • 2017 ACR/ARHP Annual Meeting

    Does Guideline-Based Care Improve Outcomes That Matter to Patients? Tighter Control, Less Suffering, and Greater Well-Being over the Past Decade in Canadian RA Patients

    Susan J. Bartlett1,2, Orit Schieir3, Marie-France Valois4, Carol A Hitchon5, Janet E. Pope6, Gilles Boire7, Boulos Haraoui8, Edward C. Keystone9, Diane Tin10, Carter Thorne11 and Vivian P. Bykerk12, 1Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 4McGill University, Montreal, QC, Canada, 5University of Manitoba, Winnipeg, MB, Canada, 6Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 7Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 8Institute de Rheumatologie, Montreal, QC, Canada, 9University of Toronto, Toronto, ON, Canada, 10The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 11University of Toronto, Newmarket, ON, Canada, 122-005, Mt Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: Best practice recommendations can increase quality of care and improve clinical outcomes, however the impact of recommendations on outcomes that matter most to patients…
  • Abstract Number: 417 • 2017 ACR/ARHP Annual Meeting

    Improvement in Overall Work Productivity Among Biologic-NaïVe Patients with Rheumatoid Arthritis Treated with Tocilizumab Subcutaneous Injection: A Prospective, Real World, Observational Study in Japan

    Yoshiya Tanaka1, Hideto Kameda2, Kazuyoshi Saito3, Yuko Kaneko4, Eiichi Tanaka5, Shinsuke Yasuda6, Naoto Tamura7, Keishi Fujio8, Takao Fujii9, Toshihisa Kojima10, Tatsuhiko Anzai11, Chikuma Hamada12, Yoshihisa Fujino13, Shinya Matsuda13 and Hitoshi Kohsaka14, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 2Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan, 3Tobata General Hospital, Fukuoka, Japan, 4Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 5Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 6Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 7Department of Internal Medicine and Rheumatology, Juntedo University School of Medicine, Tokyo, Japan, 8Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, 9Department of Rheumatism and Collagen Disease, Wakayama Medical University, Wakayama, Japan, 10Nagoya Univ. Grad. Schl. of Med., Nagoya, Japan, 11Data Science Division, Statistics Analysis Department 1, EPS Corporation, Tokyo, Japan, 12Department of Information and Computer Technology, Tokyo University of Science, Tokyo, Japan, 13Department of Preventive Medicine and Community Health, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 14Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

    Background/Purpose: This is the first study assessing the effect of subcutaneous tocilizumab (TCZ-SC) and/or conventional synthetic DMARDs (csDMARDs) on work productivity and activity impairment (WPAI)…
  • Abstract Number: 1083 • 2017 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis Patients Achieved Better Quality of Life Than Systemic Lupus Erythematosus Patients at Sustained Remission: The Impact of Disease Diagnosis on Health-Related Quality of Life Outcomes

    Virginia Pascual-Ramos1, Irazú Contreras-Yáñez2, Katya Valencia-Quiñones3 and Juanita Romero-Diaz4, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 3Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 4Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico

    Background/Purpose: Patients with Systemic Lupus Erythematous (SLE) and Rheumatoid Arthritis (RA) had profound negative effects on their health-related quality of life (HRQoL) that can be…
  • Abstract Number: 1243 • 2017 ACR/ARHP Annual Meeting

    Clarifying Patient-Determined Barriers in Living with Systemic Lupus Erythematosus Treatment: A Qualitative Ethnographic Approach

    Jerik Leung1, Deepali Sen2 and Alfred Kim3, 1Internal Medicine/Rheumatology, Washington University School of Medicine, Saint Louis, MO, 2Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, 3IM/Rheumatology, Washington University School of Medicine, St. Louis, MO

    Background/Purpose: The patient-specific experience of living with SLE is underreported. While there are data addressing factors influencing the quality of life of patients with SLE,…
  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology